Our friends at Natural Health 365 posted this article , being ignored by Bog Pharma and governments
Could a common drug called Budesonide really offer an effective, safe, and affordable COVID solution for ill patients? The answer may shock you, especially if you’ve been listening to the dire reports put out by the mainstream media.
The truth is: a Texan emergency room doctor – with nearly 30 years of experience – has some very good news for those people concerned about COVID-19. And, thankfully, he’s currently working hard to get his message out about this potentially lifesaving steroid, no matter how reluctant some government officials may be to admit its promising impact.
Medical doctor is putting the proverbial fire of COVID-19 out with budesonide
Budesonide is typically inhaled via a nebulizer, a non-invasive medical device that transforms medication into vapor so it can be breathed in by the patient through a handheld nozzle or simple face mask. The drug is commonly used to treat asthma.
Because it helps alleviate inflammation in the body, doctors also use budesonide for other reasons, including managing symptoms of Crohn’s disease and ulcerative colitis. But, according to Texas ER physician Dr. Richard Bartlett, budesonide is helping his COVID patients recover extremely quickly and without the side effects commonly seen with other heavier-duty steroid medications.
In a July 2 interview on the news show American Can We Talk, Dr. Bartlett explains:
“My silver bullet is inhaled [generic] budesonide. It’s super cheap … with insurance, many of my patients are not even having to pay for it.”
Do NOT ignore the health dangers linked to toxic indoor air. These chemicals – the ‘off-gassing’ of paints, mattresses, carpets and other home/office building materials – increase your risk of headaches, dementia, heart disease and cancer.
Get the BEST indoor air purification system – at the LOWEST price, exclusively for NaturalHealth365 readers. I, personally use this system in my home AND office. Click HERE to order now – before the sale ends.
He continues: “[Budeosnide] is a respiratory anti-inflammatory for COVID – which is a respiratory inflammatory disease – and it works.”
Dr. Bartlett has had a 100% success rate with this promising COVID treatment, and notes that many of his patients have reported feeling significantly better after just one five minute nebulizer treatment. In his clinical practice setting, he’s been treating very ill patients since March.
See for yourself by watching this wonderful interview with Dr. Bartlett – below:
“It’s common sense,” he adds bluntly.
Effective, generic, and cheap – can you guess why many Big Pharma and government officials are bent on seeing this promising new COVID treatment fail? Simply follow the money, as they say.
Dr. Bartlett has said that doctors in other countries including France and Spain are starting to explore the use of inhaled steroid medications for their COVID-19 patients. He also adds that the National Institutes of Health (NIH) will reportedly be looking into budesonide for use in the global pandemic, as well.
The big question: Will the NIH actually put its “stamp of approval” on this therapy?
Well, you may call us a bit cynical … but, we can’t help wonder just how open-minded the NIH and other officials will truly be about this drug – which admittedly can benefit from more research to confirm its usefulness and safety in the fight against COVID-19.
Because here’s the thing:
As Dr. Bartlett notes, budesonide is cheap. Extremely cheap, especially compared to the proposed COVID-19 vaccines and other treatments currently being recommended.
And if Big Pharma can’t make a decent profit on a drug used for a brand-spanking new disease that’s commanded the headlines for the better part of a year, it’s not hard to imagine how they’d be reluctant to investigate it or draw much attention to it … not when pricey vaccines are on the agenda.
We look forward to hearing more about budesonide and are curious to see whether it’ll start picking up more support in the media and scientific community.
Sources for this article include: